Skip to main content
Livermore
Livermore
ZHEN

Paradigm Biocapital Advisors LP

SEC CIK
0001855655
Latest filing
Aug 14, 2026

Holdings in Q2 2024

Holdings as of Jun 30, 2024, filed Aug 14, 2024. Long positions only; changes compare share counts with Q1 2024.

Institution overview
Positions
35
+1 vs. Q1 2024
Portfolio value
$2.61B
−$227.7M (−8.0%) vs. Q1 2024
Filed
Aug 14, 2024
SEC
Holdings of Paradigm Biocapital Advisors LP in Q2 2024
SecurityClassSharesValue% of portfolioShare changeActionHistory
NUVLNuvalent, Inc.COM4,571,678$346.8M13.3%+393,848+9.4%AddedHistory
ARGXArgenx SESPONSORED ADR538,139$231.4M8.9%−13,981−2.5%ReducedHistory
ACLXArcellx, Inc.COMMON STOCK3,848,095$212.4M8.1%+30,000+0.8%AddedHistory
RVMDRevolution Medicines, Inc.COM5,259,089$204.1M7.8%+2,344,114+80.4%AddedHistory
SRPTSarepta Therapeutics, Inc.COM947,574$149.7M5.7%−130,772−12.1%ReducedHistory
IRONDisc Medicine, Inc.COM2,704,718$121.9M4.7%+314,816+13.2%AddedHistory
MRUSMerus N.V.COM2,019,814$119.5M4.6%+2,019,814NewHistory
CRNXCrinetics Pharmaceuticals, Inc.COM2,513,302$112.6M4.3%−611,447−19.6%ReducedHistory
CERECerevel Therapeutics Holdings, Inc.COM2,330,508$95.3M3.6%00.0%UnchangedHistory
KURAKura Oncology, Inc.COM4,539,381$93.5M3.6%+1,403,994+44.8%AddedHistory
ASNDAscendis Pharma A/SSPONSORED ADR664,307$90.6M3.5%+156,355+30.8%AddedHistory
OLMAOlema Pharmaceuticals, Inc.COM7,903,600$85.5M3.3%00.0%UnchangedHistory
XENEXenon Pharmaceuticals Inc.COM2,043,280$79.7M3.0%−441,594−17.8%ReducedHistory
TARSTarsus Pharmaceuticals, Inc.COM2,435,416$66.2M2.5%−427,990−14.9%ReducedHistory
JANXJanux Therapeutics, Inc.COM1,564,452$65.5M2.5%+1,564,452NewHistory
ARVNArvinas, Inc.COM2,438,149$64.9M2.5%−176,786−6.8%ReducedHistory
LEGNLegend Biotech CorpSPONSORED ADS1,203,308$53.3M2.0%−778,698−39.3%ReducedHistory
PCVXVaxcyte, Inc.COM627,202$47.4M1.8%−612,793−49.4%ReducedHistory
YMABY-mAbs Therapeutics, Inc.COM3,870,594$46.8M1.8%+1,636,984+73.3%AddedHistory
EWTXEdgewise Therapeutics, Inc.COM2,325,449$41.9M1.6%−120,924−4.9%ReducedHistory
IMTXImmatics N.V.SHS3,421,965$39.8M1.5%+603,057+21.4%AddedHistory
VRDNViridian Therapeutics, Inc.COM2,896,349$37.7M1.4%−2,135,071−42.4%ReducedHistory
IMVTImmunovant, Inc.COM1,362,827$36.0M1.4%+563,773+70.6%AddedHistory
COGTCogent Biosciences, Inc.COM3,624,342$30.6M1.2%+3,624,342NewHistory
BBIOBridgeBio Pharma, Inc.COM1,089,492$27.6M1.1%+1,089,492NewHistory
CGEMCullinan Therapeutics, Inc.COM1,542,805$26.9M1.0%+194,790+14.5%AddedHistory
ERASErasca, Inc.COM7,250,000$17.1M0.7%+7,250,000NewHistory
CMPSCOMPASS Pathways plcSPONSORED ADS2,335,926$14.1M0.5%−55,062−2.3%ReducedHistory
APGEApogee Therapeutics, Inc.COM330,000$13.0M0.5%00.0%UnchangedHistory
VRNAVerona Pharma plcSPONSORED ADS721,087$10.4M0.4%+721,087NewHistory
ALXOAlx Oncology Holdings IncCOM1,575,605$9.50M0.4%+1,575,605NewHistory
CATXPerspective Therapeutics, Inc.COM NEW919,692$9.17M0.4%+919,692NewHistory
VORVor Biopharma Inc.COM6,457,293$6.46M0.2%00.0%UnchangedHistory
ACRVAcrivon Therapeutics, Inc.COMMON STOCK659,724$3.83M0.1%+659,724NewHistory
TCRXTScan Therapeutics, Inc.COM353,886$2.07M0.1%+353,886NewHistory

Sold out since Q1 2024 (9)

Positions held at the end of Q1 2024 that are gone from this filing.

Positions of Paradigm Biocapital Advisors LP sold out since Q1 2024
SecurityClassShares in Q1 2024Value in Q1 2024% of portfolio in Q1 2024History
IMCRImmunocore Holdings plcADS1,787,176$116.2M4.1%History
ALPNAlpine Immune Sciences, Inc.COM2,121,163$84.1M3.0%History
BCYCBicycle Therapeutics PLCSPONSORED ADS3,246,759$80.8M2.8%History
AUTLAutolus Therapeutics plcSPON ADS6,425,803$41.0M1.4%History
ZNTLZentalis Pharmaceuticals, Inc.COM944,917$14.9M0.5%History
AGIOAgios Pharmaceuticals, Inc.COM400,000$11.7M0.4%History
CRBUCaribou Biosciences, Inc.COM2,172,620$11.2M0.4%History
CRGXCARGO Therapeutics, Inc.COM147,959$3.30M0.1%History
KYTXKyverna Therapeutics, Inc.COM50,000$1.24M<0.1%History